Dear Valued Customer,
Boehringer Ingelheim has reached an agreement to sell Newport Laboratories, which manufactures custom-made vaccines for swine and cattle, to Vaxxinova.
By prioritizing our investments and focusing on key brands in our livestock portfolios, we believe we can deliver the greatest value to customers and ensure long-term growth and success in a dynamic and evolving business environment.
New award helps veterinary students pursue research into cattle health
WORTHINGTON, Minn. (May 26, 2021) – Newport Laboratories, Inc., a Boehringer Ingelheim company, is proud to announce the recipient of the first-ever Lex Thompson Veterinary Investigator Award. The award, which will be given annually to a veterinary student, recognizes an outstanding research proposal and provides the tools and support necessary to complete it.
Cattle herds exposed to infectious bovine keratoconjunctivitis, more commonly known as pinkeye, are at risk of lower calf-growth rate, potential blindness and permanent damage if left untreated.1 It’s estimated that pinkeye causes annual losses of more than $150 million in the United States, affecting over 10 million calves.1
With an emerging species of pinkeye bacteria overtaking the previously predominant species, controlling this increasingly complex disease is challenging for many producers and veterinarians. But there are tools that can help.
Newport Laboratories, Inc., a leader in custom-made vaccines, is proud to offer Bio One™, a proprietary one-dose adjuvant that helps reduce time, labor and expense by removing the need for booster shots.
Many bovine custom-made vaccines require an initial administration and a second booster shot several weeks later, but due to the added labor cost and logistical challenges associated with administering the second dose, it is commonly overlooked. This can compromise the effectiveness of the vaccine.
There are two basic ingredients in killed vaccines: antigens and adjuvants. While antigens are well understood, there’s far less understanding of the critical role adjuvants play in vaccines’ ability to do their job. But not all adjuvants are the same, and identifying which adjuvant has the right properties to help solve a herd’s health challenges can give producers and veterinarians peace of mind that they’re giving the best possible vaccine to their animals.
As producers continue to reduce the amount of antibiotics given to their herds, many are looking to other options to fight Streptococcus suis, more commonly known as Strep suis.
The pathogen is one of the primary causes of bacterial meningitis in pigs,1 and can cause illness at any stage of production, with associated mortality rates of up to 20 percent.2 With infections often existing subclinically and nearly 100 percent of pigs serving as carriers of the bacteria,3Strep suis is a key concern for many producers.
WORTHINGTON, Minn. (Sept. 4, 2018) — Newport Laboratories, Inc., a leader in livestock custom-made vaccines (CMVs), today launches HerdPoint,™ a new solution for veterinarians that streamlines the nonadjacent-herd approval process and ongoing isolate management, all from a mobile phone or computer.
DULUTH, Ga. — [June 12, 2018]
Boehringer Ingelheim (BI) is excited to announce that Newport Laboratories, Inc. in Worthington, Minnesota, is officially part of Boehringer Ingelheim’s animal health business unit.
Newport Laboratories enhances the service and product offerings for BI customers. By providing cutting-edge diagnostics like whole genome sequencing, metagenomics, and bioinformatics, Newport Laboratories crafts custom, autogenous vaccines that target the specific viruses or bacteria causing disease in individual livestock operations.
WORTHINGTON, Minn. – Veterinarian Randy Shirbroun of Newport Laboratories Inc. addressed more than 200 bison producers regarding the pathology and prevention of diseases caused by Mycoplasma bovis. The producers had gathered for the 2016 National Bison Association Summer Conference held in June at Elk River, Minnesota. Shirbroun specializes in ruminant health issues including those seen in the American bison, which became the official U.S. national mammal in May.
Newport Laboratories, Inc. has developed a new multilocus sequence typing (MLST) technique for Mycoplasma bovis, a significant cause of disease in cattle. The new technology represents a major advancement over the previous diagnostic process and will provide increased resolution and a better assessment of genetic variation that may be associated with antigenic, or strain differences.
This technological advancement utilizing molecular biology is yet another development to come from Newport Laboratories, Inc., a leader in cutting edge diagnostic technology and the manufacturer of autogenous, or custom-made vaccines. The new MLST technique evaluates 10 variable genes associated with specific Mycoplasma bovis virulence factors, including several of the variable surface proteins (VSPs).
